Preoperative Neutrophil/Lymphocyte Ratio Predicts Overall Survival and Extravesical Disease in Patients Undergoing Radical Cystectomy

Wake Forest University, Urology, Medical Center Blvd, Winston Salem, North Carolina, United States, 27157, 3367165701, , United States
Journal of endourology / Endourological Society (Impact Factor: 2.1). 03/2013; 27(8). DOI: 10.1089/end.2012.0606
Source: PubMed

ABSTRACT Objectives: To evaluate if hematologic parameters and inflammatory markers, could predict extravesical tumor and overall survival following radical cystectomy for patients with recurrent high grade T1 or muscle invasive bladder cancer. Patients and Methods: A total of 68 consecutive cases of radical cystectomy performed with curative intent at our institution between April 2005 and October 2011 with preoperative hematologic parameters are included in this analysis. We evaluated preoperative characteristics with uni and multivariate cox proportion hazard ratios to assist in risk stratification for overall survival. Relative risk ratios (RR) and 95% confidence intervals (CI) were created. We also identified factors associated with extravesical tumor extension with logistic regression analysis. Results: Median overall survival was in the total cohort was 25 months. (95% CI 13-61) In multivariate analysis, neutrophil/lymphocyte ratio < 2.5 (RR 2.49; 95% CI 1.14 - 6.09) hypoalbuminemia (RR 4.96; 95% CI 2.18 - 11.67), pT3/4 (RR 7.97, 95% CI 3.16-24.83) and lymph node positive disease predicted (RR 2.62, 95% CI 1.26-5.46) overall survival. These were statistically significant for cancer specific survival as well. Both elevated neutrophil/lymphocyte ratio (RR 3.18, 95% CI 1.09 - 9.79) and hypoalbuminemia (RR 3.72, 95% CI 1.12 - 15.00) were associated with risk for extravesical disease. Conclusions: Serum neutrophil/lymphocyte ratio and hypoalbuminemia predict overall and cancer specific survival in patients undergoing radical cystectomy for muscle invasive bladder cancer. These parameters also predict risk for extravesical disease. These could be combined with other established preoperative parameters to improve risk stratification and preoperative counseling.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Host immune response has an impact on tumour development and progression. There is interest in the use of inflammatory biomarkers (InfBMs) in cancer care. Although several studies assessing the potential prognostic value of InfBMs in cancer have been published in the past decades, they have had no impact on the management of patients with urothelial bladder carcinoma (UBC).
    European Urology 08/2014; 66(6). DOI:10.1016/j.eururo.2014.07.033 · 12.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Inflammation may play an important role in cancer progression, and a high neutrophil-to-lymphocyte ratio (NLR) has been reported to be a poor prognostic indicator in several malignancies. Here we quantify the prognostic impact of this biomarker and assess its consistency in solid tumors. METHODS: A systematic review of electronic databases was conducted to identify publications exploring the association of blood NLR and clinical outcome in solid tumors. Overall survival (OS) was the primary outcome, and cancer-specific survival (CSS), progression-free survival (PFS), and disease-free survival (DFS) were secondary outcomes. Data from studies reporting a hazard ratio and 95% confidence interval (CI) or a P value were pooled in a meta-analysis. Pooled hazard ratios were computed and weighted using generic inverse-variance and random-effect modeling. All statistical tests were two-sided. RESULTS: One hundred studies comprising 40559 patients were included in the analysis, 57 of them published in 2012 or later. Median cutoff for NLR was 4. Overall, NLR greater than the cutoff was associated with a hazard ratio for OS of 1.81 (95% CI = 1.67 to 1.97; P < .001), an effect observed in all disease subgroups, sites, and stages. Hazard ratios for NLR greater than the cutoff for CSS, PFS, and DFS were 1.61, 1.63, and 2.27, respectively (all P < .001). CONCLUSIONS: A high NLR is associated with an adverse OS in many solid tumors. The NLR is a readily available and inexpensive biomarker, and its addition to established prognostic scores for clinical decision making warrants further investigation.
    JNCI Journal of the National Cancer Institute 06/2014; 106(6-6):dju124. DOI:10.1093/jnci/dju124 · 15.16 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Measures of prognosis for cancer patients are typically evaluated at the time of diagnosis. However, this study assessed the changes in 2-year CS rates after first-line chemotherapy for metastatic UC.Patients and Methods Conditional overall survival and CPFS probability were estimated using the Kaplan–Meier method. Adjusted survival functions were stratified according to age groups (< 70 years vs. ≥ 70 years), sex, Eastern Cooperative Oncology Group (ECOG) performance status (PS; ECOG PS ≤ 2 vs. ECOG PS > 2), pretreatment Hb levels (< 12 mg/dL vs. ≥ 12 mg/dL) and pretreatment NLR (< 3 vs. ≥ 3). Pairs of CS curves were compared using the Mantel–Haenszel log-rank test.ResultsTwo hundred ninety-eight patients were included in this analysis, 233 were male, and their median age was 69 years. First-line median overall survival and progression-free survival were 10.7 months (95% confidence interval [CI], 9.6-12.6) and 6.0 months (95% CI, 5.5-7.1), respectively. CPFS and COS showed an increasing trend in the population considered (b = 0.35; P < .001 and b = 0.79; P < .001, respectively). A significant increase in terms of COS and CPFS trends was identified in patients with age < 70 years (P = .02 and P = .005, respectively) and pretreatment NLR ≤ 3 (P = .05 and P < .001, respectively). Patients with Hb levels < 12 g/dL showed a significantly poorer 2-year COS.Conclusion The conditional probability of survival at 2 years from the start of first-line chemotherapy for advanced UC changes over time according to clinical characteristics.
    Clinical Genitourinary Cancer 10/2014; 13(3). DOI:10.1016/j.clgc.2014.10.003 · 1.69 Impact Factor